Filtros de búsqueda

Lista de obras de

A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer

artículo científico publicado en 2020

A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer

artículo científico publicado en 2017

A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

scientific article published on 26 June 2019

A Phase II Trial of Dose-Dense Neoadjuvant Gemcitabine, Epirubicin, and Albumin-Bound Paclitaxel With Pegfilgrastim in the Treatment of Patients With Locally Advanced Breast Cancer ⬇️

artículo científico publicado el 1 de octubre de 2010

A Phase II Trial of Oxaliplatin and Trastuzumab in the Treatment of HER2-Positive Metastatic Breast Cancer ⬇️

artículo científico publicado el 1 de octubre de 2010

A Phase II Trial of Vinflunine As Monotherapy or in Combination with Trastuzumab as First-Line Treatment of Metastatic Breast Cancer ⬇️

artículo científico publicado el 1 de noviembre de 2010

A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer

scientific article published on 23 August 2018

A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer

artículo científico publicado en 2020

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine ⬇️

artículo científico publicado el 28 de mayo de 2011

A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors

artículo científico publicado en 2011

A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors

artículo científico publicado en 2012

A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.

artículo científico publicado en 2011

A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer

scientific article published on 02 November 2010

A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer

artículo científico publicado en 2008

A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer

artículo científico publicado en 2009

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

artículo científico publicado en 2012

A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer

artículo científico publicado en 2008

A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score

artículo científico publicado en 2015

A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer

artículo científico publicado en 2010

A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer

artículo científico publicado en 2011

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.

artículo científico publicado en 2010

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

artículo científico publicado en 2018

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

artículo científico publicado en 2009

A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

scientific article published on 10 January 2020

Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)

Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes

artículo científico publicado en 2008

Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer

artículo científico publicado en 2013

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

artículo científico publicado en 2017

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer ⬇️

artículo científico publicado en 2015

Adverse event management of mTOR inhibitors during treatment of hormone receptor-positive advanced breast cancer: considerations for oncologists

artículo científico publicado en 2014

Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial

artículo científico publicado en 2014

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

artículo científico publicado en 2014

Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs

scientific article published on 26 November 2019

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

artículo científico publicado en 2016

Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study.

artículo científico publicado en 2018

Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial

artículo científico publicado en 2004

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

artículo científico publicado en 2015

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs

artículo científico publicado en 2018

Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.

artículo científico publicado en 2011

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

artículo científico publicado en 2004

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

artículo científico publicado en 2015

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

artículo científico publicado en 2015

Clinical and laboratory features and sequelae of deficiency of folic acid (folate) and vitamin B12 (cobalamin) in pregnancy and gynecology

artículo científico publicado en 2000

Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions

artículo científico publicado en 2013

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evalu

artículo científico publicado en 2017

Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.

artículo científico

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

artículo científico publicado en 2020

Correlation of Bcl-2 and p53 expression in primary breast tumors and corresponding metastatic lymph nodes

artículo científico publicado en 2003

De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry

scientific article published on 14 October 2019

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

artículo científico publicado en 2010

Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial

artículo científico publicado en 2006

Drug resistance and the role of combination chemotherapy in improving patient outcomes

artículo científico publicado en 2013

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer

artículo científico publicado en 2015

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.

artículo científico publicado en 2015

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study

scientific article published on 28 February 2019

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

artículo científico publicado en 2018

Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized con

artículo científico publicado en 2016

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.

artículo científico publicado en 2014

Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

artículo científico publicado en 2017

Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer.

artículo científico publicado en 2015

Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.

artículo científico publicado en 2015

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.

artículo científico publicado en 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

artículo científico publicado en 2012

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis

artículo científico publicado en 2013

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

scientific article published on 12 December 2019

First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER

artículo científico publicado en 2013

Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer

artículo científico publicado en 2004

Gemcitabine and taxanes as a new standard of care in breast cancer.

artículo científico publicado en 2004

Gemcitabine plus paclitaxel in breast cancer

artículo científico publicado en 2005

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer

artículo científico publicado en 2016

Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial ⬇️

artículo científico publicado en 2017

Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents

artículo científico publicado en 2014

Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor–Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium ⬇️

artículo científico publicado el 20 de abril de 2011

In pursuit of the prevention of breast cancer

artículo científico publicado en 2000

Incidence-based cost-of-illness model for metastatic breast cancer in the United States.

artículo científico publicado en 2012

Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network

artículo científico publicado en 2002

Integrating bevacizumab into the treatment of patients with early-stage breast cancer: focus on cardiac safety

artículo científico publicado en 2010

Integrating gemcitabine into breast cancer therapy.

artículo científico publicado en 2004

Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network

artículo científico publicado en 2007

Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)

scientific article published on 19 April 2019

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.

artículo científico publicado en 2014

Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.

artículo científico publicado en 2005

MONALEESA clinical program: a review of ribociclib use in different clinical settings

scientific article published on 15 July 2019

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.

artículo científico publicado en 2017

Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction

artículo científico publicado en 2010

Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer

artículo científico publicado en 2009

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute

artículo científico publicado en 2014

Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer

artículo científico publicado en 2014

Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute

artículo científico publicado en 2015

Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network

artículo científico publicado en 2007

Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial

artículo científico publicado en 2016

Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

artículo científico publicado en 2016

Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent with Radiation Therapy for Locally Advanced Non???Small Cell Lung Cancer

Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer

scientific article published on 01 January 2006

Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck

artículo científico publicado en 2001

Phase I. Trial of irinotecan plus carboplatin in two dose schedules.

artículo científico publicado en 2003

Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer

artículo científico publicado en 2015

Phase II Study of Neoadjuvant Weekly nab-Paclitaxel and Carboplatin, With Bevacizumab and Trastuzumab, As Treatment For Women With Locally Advanced HER2+ Breast Cancer ⬇️

artículo científico publicado el 5 de mayo de 2011

Phase II open-label study of sunitinib in patients with advanced breast cancer

artículo científico publicado en 2012

Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

artículo científico publicado en 2012

Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer

artículo científico publicado en 2010

Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer

artículo científico publicado en 2012

Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer

artículo científico publicado en 2005

Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer

artículo científico publicado en 2009

Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy

artículo científico publicado en 2020

Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer

artículo científico publicado en 2009

Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer

artículo científico publicado en 2004

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer

artículo científico publicado en 2009

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

artículo científico publicado en 2015

Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

artículo científico publicado en 2014

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer

artículo científico publicado en 2013

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

artículo científico publicado en 2016

Proactive management of adverse events maintains the clinical benefit of ixabepilone

artículo científico publicado en 2009

Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.

artículo científico publicado en 2017

Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival

artículo científico publicado en 2015

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

artículo científico publicado en 2011

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer

scientific article published on 24 September 2013

Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study.

artículo científico publicado en 2016

Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer

artículo científico publicado en 2017

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

artículo científico publicado en 2013

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

artículo científico publicado en 2015

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2-metastatic breast cancer receiving single-agent chemotherapy-a comparison with MONARCH 1

artículo científico publicado en 2020

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

artículo científico publicado en 2016

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

artículo científico publicado en 2002

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

artículo científico publicado en 2015

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

artículo científico publicado en 2012

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

artículo científico publicado en 2019

Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers

scientific article published on 01 April 1999

Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial

artículo científico publicado en 2005

Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial

artículo científico publicado en 2016

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials

artículo científico publicado en 2012

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

artículo científico publicado en 2017

Taxanes in the elderly patient with metastatic breast cancer

artículo científico publicado en 2015

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]

scholarly article published in Breast Cancer: Targets and Therapy

Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.

artículo científico publicado en 2009

Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study

artículo científico publicado en 2015

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

artículo científico publicado en 2014

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study

artículo científico publicado en 2012

Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics.

artículo científico publicado en 2015

Updates in the treatment of basal/triple-negative breast cancer

artículo científico

Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy

artículo científico publicado en 2016

Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents

artículo científico publicado en 2010

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

artículo científico publicado en 2001

Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer

artículo científico publicado en 2009

nab-Paclitaxel mechanisms of action and delivery

artículo científico

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda